Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
Standard
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. / Witzel, Isabell; Loibl, Sibylle; Wirtz, Ralph; Fasching, Peter A; Denkert, Carsten; Weber, Karsten; Lück, Hans-Joachim; Huober, Jens; Karn, Thomas; Mackelenbergh, Marion von; Marmé, Frederik; Schem, Christian; Stickeler, Elmar; Untch, Michael; Müller, Volkmar.
In: BRIT J CANCER, Vol. 121, No. 12, 12.2019, p. 1009-1015.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
AU - Witzel, Isabell
AU - Loibl, Sibylle
AU - Wirtz, Ralph
AU - Fasching, Peter A
AU - Denkert, Carsten
AU - Weber, Karsten
AU - Lück, Hans-Joachim
AU - Huober, Jens
AU - Karn, Thomas
AU - Mackelenbergh, Marion von
AU - Marmé, Frederik
AU - Schem, Christian
AU - Stickeler, Elmar
AU - Untch, Michael
AU - Müller, Volkmar
PY - 2019/12
Y1 - 2019/12
N2 - BACKGROUND: The androgen receptor (AR) is discussed as a prognostic and/or predictive marker in breast cancer patients.METHODS: AR mRNA expression was analysed by RT-qPCR in breast cancer patients treated in the neoadjuvant TECHNO (n = 118, HER2-positive) and PREPARE trial (n = 321, HER2-positive and -negative). In addition, mRNA expression of the AR transcript variants 1 (AR1) and 2 (AR2) was measured.RESULTS: Regarding subtypes, high AR mRNA levels were frequent in HER2-positive (61.3%, 92/150) and luminal tumours (60.0%, 96/160) but almost absent in triple-negative tumours (4.3%, 3/69) (p < 0.0001). Overall, high AR mRNA levels were found to be associated with lower pathological complete remission (pCR) rates (OR 0.77 per unit, 95% CI 0.67-0.88, p = 0.0002) but also with better prognosis in terms of longer disease-free survival (DFS) (HR 0.57, 95% CI 0.39-0.85, p = 0.0054) and overall survival (OS) (HR 0.43, 95% CI, 0.26-0.71, p = 0.0011). In the PREPARE trial, a survival difference for patients with high and low AR1 mRNA levels could only be seen in the standard chemotherapy arm but not in the dose-dense treatment arm (OS: HR 0.41; 95% CI 0.22-0.74 vs. HR 1.05; 95% CI 0.52-2.13; p = 0.0459).CONCLUSIONS: We provide evidence that AR mRNA predicts response to chemotherapy in breast cancer patients.
AB - BACKGROUND: The androgen receptor (AR) is discussed as a prognostic and/or predictive marker in breast cancer patients.METHODS: AR mRNA expression was analysed by RT-qPCR in breast cancer patients treated in the neoadjuvant TECHNO (n = 118, HER2-positive) and PREPARE trial (n = 321, HER2-positive and -negative). In addition, mRNA expression of the AR transcript variants 1 (AR1) and 2 (AR2) was measured.RESULTS: Regarding subtypes, high AR mRNA levels were frequent in HER2-positive (61.3%, 92/150) and luminal tumours (60.0%, 96/160) but almost absent in triple-negative tumours (4.3%, 3/69) (p < 0.0001). Overall, high AR mRNA levels were found to be associated with lower pathological complete remission (pCR) rates (OR 0.77 per unit, 95% CI 0.67-0.88, p = 0.0002) but also with better prognosis in terms of longer disease-free survival (DFS) (HR 0.57, 95% CI 0.39-0.85, p = 0.0054) and overall survival (OS) (HR 0.43, 95% CI, 0.26-0.71, p = 0.0011). In the PREPARE trial, a survival difference for patients with high and low AR1 mRNA levels could only be seen in the standard chemotherapy arm but not in the dose-dense treatment arm (OS: HR 0.41; 95% CI 0.22-0.74 vs. HR 1.05; 95% CI 0.52-2.13; p = 0.0459).CONCLUSIONS: We provide evidence that AR mRNA predicts response to chemotherapy in breast cancer patients.
U2 - 10.1038/s41416-019-0630-3
DO - 10.1038/s41416-019-0630-3
M3 - SCORING: Journal article
C2 - 31728025
VL - 121
SP - 1009
EP - 1015
JO - BRIT J CANCER
JF - BRIT J CANCER
SN - 0007-0920
IS - 12
ER -
